Method for treating for painless myocardial ischemia disease

FIELD: medicine.

SUBSTANCE: method involves administering Eucanol at a daily dose of 3-4 g and Ispradin at a daily dose of 1.2-1.3 mg twice a day. Eucanol is taken during a meal and Ispradin is taken 30-40 min before meals.

EFFECT: enhanced effectiveness of treatment; reduced drug consumption.

 

The invention relates to medicine and can be used for the treatment of painless myocardial ischemia.

There is a method of treatment of myocardial ischemia, including the use of [[4-(1,4,5,6-TETRAHYDRO-4-METHYL-6-OXO-3-PYRIDAZINYL)PHENYL]-HYDRAZONO]PROPANEDINITRILE (RF patent No. 2146142, 2003). This method is adopted for the similar.

There is a method of treatment of painless myocardial ischemia, comprising applying a transdermal forms of micropreparative. Apply transdermal application form of nitroglycerin used to treat stable angina (Ino-Oka E, Sagawa K, Takahashi T, Inooka H, Kutsuwa Y, Umeda S. Efficacy of anti-anginal drugs in the treatment of angina pectoris associated with silent myocardial ischemia: importance of quantitative Holter ECG data for patient activity. Intern Med. 2000 Dec; 39(12):1027-37). This method is adopted for the prototype.

However, the effectiveness of this method in patients with painless myocardial ischemia is relatively limited.

The aim of the invention is to increase the effectiveness of treatment of painless myocardial ischemia.

The technical result is achieved by the fact that as a drug use eikonal in a daily dose of 3-4 g and isradipine in a daily dose of 1.2-1.3 mg, divided into 2 doses, and isradipine take 30-40 minutes before eating, and eikonal during the meal.

The technical essence of the invention is illustrated as follows.

Syndrome myocardial ischemia, do not resist ordosica angina or its equivalents, called a "silent", "silent", "asymptomatic" or "painless". Painless myocardial ischemia detected in all forms of CHD. Its presence increases the risk of sudden death or myocardial infarction and is a sign of adverse outcome.

For reliable confirmation of painless myocardial ischemia apply methods of long-term (daily) monitoring of ECG, study contractility of various departments of the myocardium and coronary perfusion, including when conducting load tests. However, the comparative diagnostic value of different detection methods of painless myocardial ischemia in patients with coronary heart disease remains poorly understood.

The basis of pathogenesis of painless myocardial ischemia in approximately 25% of cases of major importance is the reduction of coronary blood flow, probably due to vasoconstriction. There is an option of painless myocardial ischemia without ECG changes - "hidden", "secret" ischemia, which is revealed only by using scintigraphy of the myocardium. The occurrence of episodes of painless myocardial ischemia observed during intense mental activity, emotional stress, and Smoking.

It is believed that any myocardial ischemia, including painless, requires treatment with the use of antianginal drugs of different classes. However, it is shown that h is about when taking nitrates and nifedipine may occur or increase episodes of painless myocardial ischemia.

We proposed as drug use eikonal in a daily dose of 3-4 g of 2 admission during meals with a preliminary introduction of isradipine 1,2-1,3 mg Joint application of Akinola and isradipine allowed to reduce the dose of either drug, which is very important, because the prescription drug eikonal in the standard dose of 6-8 g once at the reception are very often poorly tolerated. In addition, the joint appointment of Akinola and isradipine despite a reduction in dose of the drugs can achieve the purpose of the invention is to improve the effectiveness of the treatment is painless myocardial ischemia.

The method is as follows.

At admission the patient complains of pain in the legs when walking, dizziness, numbness of the feet, paresthesia, dry mouth, thirst, frequent urination, evening subfebrility, General weakness.

From the anamnesis it is known that the patient frequently have heart rhythm disturbances, increased blood pressure to 190/100 mm Hg (pressure of 150/80 mm Hg). Taking isradipine, diuretics.

Objectively: the state of moderate severity. Patient asthenic physique. The skin is dry and pale. Skin turgor is reduced. Peripheral edema no.

In the lungs breathing weakened in secondary departments, no wheezing, BH - 18 in 1 min muffled heart sounds, rhythmic, ccent II tone on the pulmonary artery, HR - 82 1 min, AD - 190/100 mm Hg pulsation of the arteries of the feet is reduced.

Tongue dry, white furred. The abdomen is soft, painless. The liver is 1 cm from the edge of the costal arch, the edge of the soft, elastic. Spleen not palpated. Dysuric phenomena not.

The clinical analysis of blood without pathology. ECG sinus rhythm, a single atrial extrasystoles. Blockade of the anterior branch of the left bundle branch. Changes in the myocardium of the left ventricle with its hypertrophy.

Determine blood lipid profile: total cholesterol, TG, LDL-VLDL, LDL-C, HDL-C.

Measure the total peripheral vascular resistance (SVR), cardiac index (MI), stroke volume (PP), end-diastolic volume (BWW), end-systolic volume (CSR) and ejection fraction (EF).

When Holter monitoring revealed episodes of painless myocardial ischemia more than 10 minutes per day.

Assessing dyscirculatory disorders and change psihoolgicheskoy areas on a scale of DSM - III-R.

On the basis of the survey diagnosed with CHD, painless myocardial ischemia, myocardial infarction, atrial fibrillation, arterial hypertension.

Treatment: eikonal in a daily dose of 3-4 g and isradipine in a daily dose of 1.2-1.3 mg, divided into 2 doses, and isradipine take 30-40 minutes before eating, and eikonal during meals; m is cheganye, aspirin, trental, vitamins of group of Century

In therapy of symptoms of painless myocardial ischemia (painless myocardial ischemia) disappeared. Improved neurological status and state of psycho-emotional sphere.

Re-examination before discharge showed a reduction in pain in the legs when walking, which was accompanied by increase of the distance free distance.

Blood lipid spectrum is normalized. The performance of the ECHO-KG - positive dynamics. By Holter monitoring episodes of painless myocardial ischemia was not detected.

On a background of treatment noted positive dynamics of the current disease in the form of reduced requirements eikonal and isradipine, diuretics, aspirin.

Subsequent follow-up monitoring within 8-12 months. confirmed the accuracy of the diagnosis and showed the correctness of the treatment.

Way of the following examples.

Example 1.

Patient M., 78 years of age.

Diagnosis at admission: CHD, painless myocardial ischemia, myocardial infarction, atrial fibrillation. The syndrome of intermittent claudication. Non-insulin-dependent diabetes mellitus, heavy flow. Diabetic retinopathy, diabetic nephropathy, microangiopathy of the lower extremities, peripheral polyneuropathy.

Complaints at admission for pain in the legs when is odibe, dizziness, numbness of the feet, dry mouth, thirst, frequent urination.

History: In 1975 he had a heart attack, suffer from high blood pressure for 18 years with a maximum lifting 210/120 mm Hg Takes korinfar, diuretics. Chronic pyelonephritis since 1980. Suffering from diabetes for 18 years. Compensation of carbohydrate metabolism was performed oral hypoglycemic agents (maninil 3 t/day and glurenorm 2 t/day). Diabetes mellitus complicated by diabetic retinopathy stage III, diabetic polyneuropathy, encephalopathy. The deterioration in the last 2 weeks, when appeared the above complaints, what was the reason for hospitalization.

Objectively: the state of moderate severity. Patient asthenic physique. The skin is dry and pale. Skin turgor is reduced. Peripheral edema no.

In the lungs breathing weakened in secondary departments, no wheezing, BH - 20 in 1 min muffled heart sounds, rhythmic accent of II tone on the pulmonary artery, HR - 88 1 min, AD - 190/100 mm Hg pulsation of the arteries of the feet is reduced.

Tongue dry, white furred. The smell of acetone in exhaled air no. The abdomen is soft, painless. The liver performs at 1.5 cm from the edge of the costal arch, the edge of the soft, elastic. Spleen not palpated. Dysuric phenomena not.

the Glycaemia at admission - to 20.8 mmol/l, glucosuria - 2%

The clinical analysis of blood without pathology. ECG sinus rhythm, a single atrial extrasystoles. Blockade of the anterior branch of the left bundle branch. Changes in the myocardium of the left ventricle with its hypertrophy.

Blood lipid profile. Total cholesterol - 7.8 mmol/l, TG - 3.04 mmol/l, LDL-VLDL - 1.38 mmol/l, LDL-C - 2.36 mmol/l, HDL-C - 0.98 mmol/l

USDG great vessels of the head and neck. Carotid artery - LSC Sc - 100 cm/sec, dc - 70 cm/sec, vertebrates Sv - 15 cm/sec. Consultation of the neurologist: diabetic peripheral polyneuropathy.

Measure the total peripheral vascular resistance (SVR), cardiac index (MI), stroke volume (PP), end-diastolic volume (BWW), end-systolic volume ( CSR) and ejection fraction (EF) and find their values: UO - 61.9 cm, PV - 54.9%, BPA - 110.0 mm Hg, SVR - 1493.9 Dyne/cm/sec - 5, C - 2577.9 ml/m2, BWW - 129.5 cm3CSR - 65.9 cm3. When Holter monitoring revealed episodes of painless myocardial ischemia 11 minutes per day.

Treatment: eikonal in a daily dose of 3 g, divided into 2 doses at meal times, with a preliminary introduction for 30 min isradipine at a dose of 1.2 mg divided into 2 doses per day; in addition, were appointed diuretics, aspirin, trental, vitamins gr. In V/m; insulin (regular insulin 38 IU/day at 4-fold in the introduction).

Provedenie dyscirculatory disorders and change psihoolgicheskoy areas on a scale of DSM - III-R. Lucidity - 5 points, memory for current events - 5 points, dizziness - 3 points. Hearing disorders - 5 points.

To 28 days of therapy symptoms of painless myocardial ischemia disappeared.

Improved neurological status and state of psycho-emotional sphere, which corresponded to the reduction of points on a scale of DSM - III-R (lucidity - 1, memory for events - 3, headache - 1, vertigo - 1, NAP - 3, hearing disorders - 3).

Re-examination before discharge on day 31. Decreased pain in the legs when walking, which was accompanied by increase of the distance free walk 300 m to 900 m Signs of decompensation of diabetes mellitus no. Thirst, dry mouth, polyurea bother. Fasting glucose 10.9 mmol/l, in urine glycosuria.

Blood lipid profile. Total cholesterol - 5.9, TG - 1.96, LDL-VLDL - 0.89 mmol/l, LDL-C - 2.27, HDL-C - 1.12. The ECHO-KG: PP - 83.2 cm, PV - 58.9%, AD cf - 106.7 mm Hg, SVR - 1352 Dyne/cm/sec - 5, C 3727.4 ml/m2, BWW - 117,4 cm3CSR - 58.1 cm3.

On a background of treatment noted positive dynamics of the current disease. Follow-up observation for 8 months showed positive dynamics after treatment.

Example 2.

Sick As in, 71.

Diagnosis: ischemic heart disease, painless myocardial ischemia, myocardial infarction, atrial fibrillation.

Complaints when the pic is upline of shortness of breath, occur during exercise, evening subfebrility, General weakness.

From the anamnesis it is known, that the patient had marked improvement in blood pressure for the past 17 years, maximum digits HELL 190/100, the usual 150/80 mm Hg Takes korinfar, diuretics.

Objectively: the state of moderate severity, the patient giperstenicheskom physique. The skin is dry and pale. Skin turgor is reduced. Peripheral edema no.

In the lungs breathing weakened in the lower divisions, no wheezing, BH - 16 in 1 min muffled heart sounds, rhythmic accent of II tone of the aorta and pulmonary artery, heart rate 92 in 1 minute

The abdomen is soft, painless. Liver at the edge of the costal arch. Spleen not palpated. Dysuria is not.

The clinical analysis of blood without pathology. ECG sinus rhythm, single ventricular extrasystoles. Marked diffuse changes of a myocardium of the left ventricle.

Blood lipid spectrum:. TC - 7.5 mmol/l, TG - 3.0 mmol/l, LDL-VLDL - 1.34 mmol/l, LDL-C - 2.4 mmol/l, HDL-C - 0.95 mmol/l

USDG great vessels of the head and neck. Carotid artery - LSC Sc - 110 cm/sec, dc - 80 cm/sec, vertebrates Sv - 20 cm/sec.

Measure the total peripheral vascular resistance (SVR), cardiac index (MI), stroke volume (PP), end-diastolic volume (BWW), end-systolic volume (CSR) and ejection fraction (EF) and n is go to their values: UO - 60.4 cm, PV - 52.0%, BPA - 130.0 mm Hg, SVR-1498.7 Dyne/cm/sec-5, C - 2614.9 ml/m2, BWW - 131.3 cm3CSR - 69.3 cm3. Evaluation of dyscirculatory disorders and change psihoolgicheskoy areas on a scale of DSM. When Holter monitoring revealed episodes of painless myocardial ischemia 18 minutes per day.

Treatment: eikonal in a daily dose of 3.5 g, divided into 2 doses at meal times, with a preliminary introduction for 35 min isradipine at a dose of 1.25 mg, divided into 2 doses per day, diuretics, aspirin, trental. 25 days of therapy symptoms of painless myocardial ischemia disappeared.

Improved neurological status and state of psycho-emotional sphere, which corresponded to the reduction of points on a scale of DSM - III-R: indicators of clarity of consciousness, memory for events, headache, dizziness, sleep, hearing disorders improved by 20-25%.

Re-examination before discharge on day 31. Decreased pain in the legs when walking, which was accompanied by increase of free walking distances from 400 meters to 1100 meters

Blood lipid profile, total cholesterol - 5.9, TG - 1.96, LDL-VLDL - 0.89 mmol/l, LDL-C - 2,2, HDL-C - 1.12.

The ECHO-KG: PP - 73.2 cm, PV - 58.9%, AD cf - 106.7 mm Hg, SVR - 1348 Dean./cm/sec - 5, C 2841.4 ml/m2, BWW - to 121.6 cm3CSR - 58.1 cm3. By Holter monitoring episodes of painless myocardial ischemia was not detected.

Subsequent follow-up observation for 16 months confirmed the accuracy of the diagnosis and showed the correctness of the treatment.

Example 3.

Patient P., 68.

Diagnosis: ischemic heart disease, painless myocardial ischemia, myocardial infarction. Arterial hypertension.

Complaints when entering the dizziness and numbness in her feet, paresthesia, General weakness.

From the anamnesis it is known that the patient is in the last 22 years has been the increase in blood pressure, maximum digits HELL reach 200/110 mm Hg Takes diuretics.

Objective indicators: a state of moderate severity, the patient giperstenicheskom physique. The skin is dry and pale. Skin turgor is reduced.

In the lungs vesicular breathing, wheezing no, BH - 19 in 1 min muffled heart sounds, rhythmic, HR - 86 1 min, AD - 190/100 mm Hg

Tongue coated Belm bloom. The abdomen is soft. The liver stands out from the edge of a costal arch on 1.5 cm, soft edge. Dysuric phenomena not observed

Blood lipid profile. Total cholesterol - 8.1 mmol/l, TG - 3.34 mmol/l, LDL-VLDL - 1.46 mmol/l, LDL-C - 2.64 mmol/l, HDL-C - 0.86 mmol/L.

USDG great vessels of the head and neck. Carotid artery - LSC Sc - 95 cm/sec, dc - 74 cm/sec, vertebrates Sv - 19 cm/sec, Dv - 24 cm/sec.

Definition PP - 63.4 cm, PV - 52.7%, BPA - 115.0 mm Hg, SVR - 1513.0 Dyne/cm/sec - 5, C - 2586.0 ml/m2/sup> , BWW - 137.4 cm3CSR - 67.7 cm3. Evaluation of dyscirculatory disorders and changes psihoolgicheskoy areas on a scale of DSM. When Holter monitoring revealed episodes of painless myocardial ischemia 25 min per day.

Treatment: eikonal in a daily dose of 4 g, divided into 2 doses at meal times, with a preliminary introduction for 40 min isradipine dose of 1, 3 mg, divided into 2 doses per day for 40 min before meals; diuretics, aspirin.

To 26 days of therapy eliminated symptoms of painless myocardial ischemia. In terms of scale DSM - III-R has improved neurological status and state of psycho-emotional sphere.

The results of the re-examination before discharge on day 32. Was a decrease in subjective complaints. By Holter monitoring episodes of painless myocardial ischemia was not detected. Blood lipid spectrum is normalized. The patient was discharged in a state of clinical and laboratory remission.

Subsequent follow-up observation for 8 months confirmed the positive dynamics of the current disease.

Example 4.

Patient P., 51.

Clinical diagnosis: ischemic heart disease. Painless myocardial ischemia. Asthmatic equivalents angina Hypertension Art. II MK II (NYNA).

Was admitted to the hospital with complaints of shortness of breath that occur up to 7 times per day and in case of habitual physical activity and at rest. Daily nitroglycerin was 14-16 tablets. Smokes for many years. Suffers from angina 7-8 years. In 1991, underwent surgery coronary artery bypass surgery in wnch AMI USSR. Within one year after the surgery I felt good, angina significantly oreilys. However, in recent years, noted the emergence and increased asthma attacks, shortness of breath when walking, swelling of the legs to the end of the day. Hypertension affects about 4 years, maximum AD 180/110 mm Hg, the usual HELL 130/80 mm Hg

When receiving a satisfactory condition. The skin is a normal color and moisture. Peripheral edema no. In the lungs breathing hard, no wheezing. Percutere heart expanded to the left. Muffled heart sounds. HR - 76 minutes, regular rhythm. HELL 160/90 mm Hg Liver, spleen not enlarged.

When the Echo-KG diastolic dimensions of the left ventricle - 5.1 cm, left atrial - 3.3 cm, the thickness of the posterior wall of the left ventricle and interventricular septum - 0,9 see Hypokinesia interventricular septum of 0.1 - 0.2 cm, normokinetic back wall - 1,4 see the Conclusion: ischemic heart disease. Hypokinesia of the interventricular septum.

When ECG monitoring for 10 hours before treatment revealed 18 painless episodes of myocardial ischemia duration 41 minutes

For treatment as a drug used in isout eikonal in a daily dose of 3.5 g and isradipine in a daily dose of 1.25 mg, divided into 2 doses, and isradipine take 30-40 minutes before eating, and eikonal - during the meal.

After treatment according to the claimed method asthma attacks stopped, clinically increased tolerance to physical load, normalized HELL. When re-ECG-ST monitoring registered just 1 ischemic episode with a duration of 22 minutes With ECG-ST monitoring is not registered ischemic episodes.

Therefore, in a patient with painless myocardial ischemia using isradipine and Akinola led to persistent anti-ischemic effects.

Example 5.

Patient A., 38 years old.

Clinical diagnosis: ischemic heart disease. Painless myocardial ischemia. Hypertension II senior Complaints at admission to the feeling of a lump in the throat and the feeling of interruptions in the heart that occurs when walking fast, emotional stress, intractable alone.

Suffers from such phenomena about 5 years. The same amount of time marks the periodic raising Hell to 180/90 mm Hg, the usual Ad-140/80 mm Hg

The condition is satisfactory. Peripheral edema no. Vesicular breathing in lungs. Percutere heart expanded slightly to the left. Muffled heart sounds. Heart rate is 72 / min, regular rhythm. Hell 160/95 mm Hg Liver is not enlarged.

Before treatment ECG ST-monitoring identified 7 painless ischemic episode about what Oliclinomel 35 minutes

As drug use eikonal in a daily dose of 3 g and isradipine in a daily dose of 1.2 mg divided into 2 doses, and isradipine take 30-40 minutes before eating, and eikonal during the meal.

As a result of the treatment the sense of disruption heart completely stopped, HELL decreased to 130/80 mm Hg In ECG-ST monitoring in the dynamics of ischemic episodes were not recorded.

In a patient with painless angina full antiischemic effect was achieved only in case of joint application of Akinola and isradipine.

The treatment according to the claimed method 47 patients. In 42 patients with subsequent follow-up observation revealed positive dynamics of the heart and emotional.

The method of treatment of painless myocardial ischemia using drugs, characterized in that as a drug use eikonal in a daily dose of 3-4 g and isradipine in a daily dose of 1.2-1.3 mg, divided into 2 doses, and isradipine take 30-40 minutes before eating, and eikonal during the meal.



 

Same patents:

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to pharmaceutically acceptable salts of 2,4,6-trimethyl-2-hydroxypyridine with lower dicarboxylic acids of the general formulae (1-a-d): possessing an antioxidant activity wherein X means a simple bond (compound 1a), oxalate, C8H11NO x C2H2O4; X means -CH2 (compound 1b), malonate, C8H11NO x C3H4O4; X means -CH2-CH2 (compound 1c), succinate, C8H11NO x C4H6O4); X means the group -CH2CH(OH) (compound 1d), malate, C8H11NO x C4H6O5. Also, invention relates to a pharmaceutical composition of salt of the formula (1c) possessing geroprotecting and anti-ischemic activities, and to a method for preparing these salts.

EFFECT: improved preparing method, valuable medicinal properties of substances and pharmaceutical composition.

3 cl, 5 tbl, 6 ex

FIELD: medicine.

SUBSTANCE: method involves additionally administering vitamins B6, B12 and folic acid to patients receiving anticoagulation therapy. Protein content is limited in daily food allowance to 0.8-1.1 g/kg of body weight and cysteine content is increased to 400-500 mg/day.

EFFECT: enhanced effectiveness of treatment; eliminated homocysteine link in pathogenesis.

FIELD: medicine.

SUBSTANCE: method involves administering Clonidine (Clophelinum). The drug is introduced intramuscularly, intravenously or as pills on the background of neurotropic therapy at a dose of 2.5-3.0 mcg/kg of body weight during the first hours of posttraumatic period within 7-10 days.

EFFECT: accelerated and simplified treatment course.

1 dwg, 1 tbl

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to derivatives of 5-amidino-2-hydroxybenzenesulfonamide of the general formula (I): wherein R2 means hydrogen atom (H), lower alkyl that can comprise a substitute chosen from the group (A): wherein (A) means -COORA, -CONRBRC, 3-7-membered monocyclic heterocycloalkyl group comprising one or two heteroatom in ring chosen from atoms N, O, S that can comprise oxo-group and 5-6-membered monocyclic aromatic heterocyclic group comprising one-three heteroatoms in ring chosen from atoms N, O, S that can comprise oxo-group or lower alkyl wherein RA means hydrogen atom (H), 3-7-membered monocyclic aliphatic alkyl group, lower alkyl that can comprises a substitute chosen from the group (i) wherein (i) means -COORA1 wherein RA1 means hydrogen atom (H), -OCORA2 wherein RA2 means lower alkyl group, -OCOORA3 wherein RA3 means lower alkyl, -ORA4 wherein RA4 means hydrogen atom (H), lower alkyl -CONRA5RA6 wherein RA5 and RA6 mean independently hydrogen atom (H), lower alkyl, or -NRA5RA6 forms 5-6-membered monocyclic amino-group comprising one heteroatom in ring chosen from atoms N, O, S and another one distinct from nitrogen atom (N) instead a bond; wherein RB and RC mean independently hydrogen atom (H), lower alkyl that can comprise a substitute chosen from the group (ii), or -NRBRC forms 5-6-membered monocyclic amino-group comprising one heteroatom in ring chosen from atoms N, O, S and another one distinct from nitrogen atom (N) instead a bond; (ii) means -COORB1 wherein RB1 means hydrogen atom (H), lower alkyl; T means oxygen atom (O), sulfonyl group; or TR1 means -SO2NRB3RC3 wherein RB3 and RC3 means independently hydrogen atom (H), lower alkyl; R2 means lower alkyl, phenyl that can comprise one-three substitutes chosen from the group (B) wherein (B) means halogen atom, -COORE, sulfamoyl, lower alkylsulfonyl wherein RE means lower alkyl; Q means hydrogen atom (H), lower alkyl that can comprise a substitute chosen from the group (D) wherein (D) means 5-6-membered monocyclic aromatic heterocyclic group that can comprise one-three heteroatom chosen from atoms N, O, S that can comprise a substitute chosen from the group (iv) wherein (iv) means oxo-group, lower alkyl; Z means hydrogen atom (H), hydroxyl group (OH), -COORN wherein RN means lower alkyl that can comprise a substitute chosen from the group (viii) wherein (viii) means -OCOR5 wherein RN5 means lower alkyl that can comprise -OCORN51 wherein RN51 means lower alkyl; or its pharmaceutically acceptable salt. Compounds of the formula (I) inhibit activated factor X in blood coagulation system that allows their using in pharmaceutical composition. Also, invention describes intermediate compounds.

EFFECT: valuable medicinal properties of compounds and compositions.

12 cl, 5 tbl

FIELD: medicine, cardiology.

SUBSTANCE: invention proposes an agent for correction of abdominal complications in acute period in myocardium infarction. Proposed agent represents ondansetron or domperidone. Agent reduces frequency of hyperemia occurring, improved indices of intestine contractions, promotes to declining lethality in acute period in myocardium infarction.

EFFECT: improved and valuable medicinal properties of agent.

4 tbl, 6 dwg

FIELD: medicine, pharmacy.

SUBSTANCE: invention proposes a pharmaceutical preparation based on angiotensin-converting enzyme inhibitor, its using in prophylaxis of insult, diabetes and/or congestive cardiac insufficiency and corresponding methods for its using in patient with maintenance heart function and subjected for risk of cardiovascular attack due to previous history of ischemic disease, insult or peripheral arterial disease. In particular, inhibitor of angiotensin-converting enzyme can be chosen from ramipril, ramiprilat, lisinopril, enalapril and enalaprilat. Invention promotes to reducing the total lethality of patients group in case of cardiovascular diseases, cardiac attacks and insults, the necessity for carrying out procedures for revascularization (such as surgery operation for coronary shunt, angioplasty with using balloon and so on) and diabetic complication are diminished.

EFFECT: improved and valuable medicinal properties of preparations.

19 cl, 1 ex

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to using a pharmaceutical preparation comprising beta-blocking agent in the maintenance dose less 50 mg, in particular, in the range from 25 mg to 47 mg in mixture with a pharmaceutically acceptable adjuvant, vehicle or carrier. The preparation is used in treatment of atherosclerosis and diseases associated with thereof. Invention provides decreasing dose of the preparation.

EFFECT: improved using method.

6 cl, 3 tbl, 1 ex

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to derivative of triazaspiro[5.5]undecane of the formula (I): wherein R1 means compound of the formula (1): or (2): wherein G represents a bond, (C1-C4)-alkylene, (C2-C4)-alkenylene or -CO-; ring A represents: (1) C5-10-membered mono- or bicarbocyclic ring or (2) 5-10-membered mono- or bicyclic heterocycle comprising 1-2 nitrogen atoms and/or 1-2 oxygen atoms; substitute R6 means the following values: (1) (C1-C4)-alkyl, (2) halogen atom, (3) nitrile group, (4) trifluoromethyl group and others; R2 represents: (1) (C1-C4)-alkyl, (2) (C2-C4)alkynyl or (3) (C1-C4)-alkyl substituted with a substitute represented in claim 1 of the invention claim; each R3 and R4 represents independently: (1) hydrogen atom, (2) (C1-C4)-alkyl or (3) (C1-C4)-alkyl substituted with 1-2 substituted taken among: (a) Cyc 2 and (b) hydroxy-group (wherein Cyc 2 represents (1) C5-6-membered monocarbocyclic ring or (2) 5-6-membered monocyclic heterocycle comprising 1-2 nitrogen atoms and/or one oxygen atom), or R3 and R4 form in common group of the formula: wherein R26 represents (C1-C4)-alkyl or Cyc 2; R5 represents hydrogen atom or (C1-C4)-alkyl, its quaternary ammonium salt, its N-oxide or its nontoxic salt. Also, invention relates to pharmaceutical composition inhibiting HIV, regulator of chemokine/chemokine receptor and agent used in treatment and prophylaxis of some diseases, such as inflammatory diseases, asthma, atopic dermatitis, nettle rash, allergic diseases, nephritis, hepatitis, arthritis and other diseases that comprise as an active component above described compound of the formula (I) or its quaternary ammonium salt, its N-oxide or its nontoxic salt. Also, invention relates to (3R)-1-butyl-2,5-dioxo-3-((1R)-1-hydroxy-1-cyclohexylmethyl)-9-(4-(4-carboxyphenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane or its pharmaceutically acceptable salt and pharmaceutical composition based on thereof, and to (3R)-1-butyl-2,5-dioxo-3-((1R)-1-hydroxy-1-cyclohexylmethyl)-9-(4-(4-carboxyphenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane hydrochloride and pharmaceutical composition based on thereof.

EFFECT: valuable medicinal properties of derivative and composition.

16 cl, 32 ex

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention proposes phenylpyridazine compounds represented by the following formula (I): wherein R1 represents unsubstituted or substituted phenyl wherein substitutes are taken among the group comprising halogen atom, lower alkyl, lower alkoxy-group and phenylthio-group, or pyridyl; R2 represents lower alkoxy-group, lower alkylthio-group, lower alkylsulfinyl or lower alkylsolfonyl; R3 represents hydrogen atom or lower alkoxy-group; or R2 and R3 can be condensed in common forming lower alkylenedioxy-group; R4 represents cyano-group, carboxyl, unsubstituted or substituted lower alkyl wherein substitutes are taken among the group comprising hydroxyl, carboxyl and N-hydroxy-N-lower alkylaminocarbonyl; lower alkenyl; lower alkylthio-group; lower alkylsulfinyl; lower alkylsulfonyl; lower alkylsulfonyloxy; unsubstituted or substituted phenoxy-group wherein substitutes are taken among the group comprising halogen atom, lower alkoxy-, nitro-, cyano-group; unsubstituted phenylthio-group or phenylthio-group substituted with halogen atom; pyridyloxy-; morpholino-group; morpholinylcarbonyl; 1-piperazinylcarbonyl substituted with lower alkyl; unsubstituted or substituted amino-group wherein substitutes are taken among the group comprising lower alkyl, benzyl, phenyl that can be substituted with halogen atoms or lower alkoxy-groups, and n = 0, or their salts. Proposed compounds possess the excellent inhibitory activity against biosynthesis of interleukin-1β and can be used in preparing a medicinal agent inhibiting biosynthesis of interleukin-1β, in particular, in treatment and prophylaxis of such diseases as diseases of immune system, inflammatory diseases and ischemic diseases. Also, invention proposes intermediate compounds for preparing compounds of the formula (I). Except for, invention proposes a medicinal agent and pharmaceutical composition that inhibit biosynthesis of interleukin-1β and inhibitor of biosynthesis of interleukin-1β.

EFFECT: valuable medicinal properties of compounds and composition.

7 cl, 1 tbl, 66 ex

FIELD: medicine and veterinary.

SUBSTANCE: invention relates to method for prophylaxis of oncological diseases, or infections mordibidized by bacteria or fungi and protozoa, or arteriosclerosis, or diabetes mellitus, or diseases mediated by delayed hyperresponsiveness reaction, or diseases mediated by somatic cell gene mutations. In the first embodiment of invention blood extracellular DNA destroying agent, such as DNAase, is administered into blood. In the second embodiment agent, binding to blood extracellular DNA, such as anti-DNA antibody is administered into blood. According to the third embodiment enzyme altering of blood extracellular DNA chemical structure is administered into blood. According to the forth embodiment agent, stimulating synthesis and/or activity of endogenic deoxyribonuclease or agent stimulating synthesis of antibody binding to blood extracellular DNA are administered into blood.

EFFECT: effective method for treatment of abovementioned diseases without side effects when prolonged using of preparation affected on blood extracellular DNA.

7 cl, 11 tbl, 18 ex, 5 dwg

FIELD: cosmetology, esthetic surgery, applied biopharmacology.

SUBSTANCE: invention relates to medicative and cosmetic agents, and uses of biologically active substances based on natural biological complexes. Claimed method includes application of Mirralgin balm having analgesic, anti-inflammation and resolving action, Reventon balm, having vessel restorative action, for edema reducing and microcirculation improving. In process of blepharoplastic eye boundary bandage microemulsion having recovery and animative action on eaves skin is applied, and in process of facelifting cream mask having bactericide, vessel restorative and recovering action, and enhancing of local immunity is applied. Mirralgin balm and Reventon balm treatment is carried out sequentially or alternatively. In another embodiment after skin cleaning and treatment of damaged zone with anti-septic agent Bacteriophage gel, which disinfects skin surface, prevents biofilm forming, accelerates cicatrizing process is applied, then posttraumatic zone is treated with cleaning milk, toned up with tonic lotion and cream mask having bactericide, vessel restorative and recovering action, and enhancing of local immunity is applied.

EFFECT: method for skin structure recovering without skin trauma.

4 cl, 7 ex, 1 tbl

FIELD: biotechnology.

SUBSTANCE: claimed method includes utilization of acetic acid as cartilage eluating solvent. According the second embodiment method includes additional filtration of solution containing crude proteoglycan to remove precipitate from said solution. Then filtered solution is centrifuged, ethanol saturated with sodium chloride is added to obtained supernatant, and supernatant is centrifuged to concentrate abovementioned crude proteoglycan in precipitate. According the third embodiment method additionally includes dissolution of said precipitate with acetic acid. Proteoglycan obtained by method of present invention may bi administered perorally.

EFFECT: simplified and environmentally friendly method for proteoglycan production.

3 cl, 3 dwg, 1 ex, 2 tbl

FIELD: medicine, drug production.

SUBSTANCE: claimed method for production of heterogeneous deoxyribonucleic acid (DNA) sodium salt from animal male gonads and/or sperm thereof includes grinding and homogenization of starting raw materials in detergent solution, solution treatment at elevated temperature with simultaneous stirring, liquid phase separation by filtering and product precipitation with alcohol. Homogenization is carried out in 1-4 % sodium dodecyl sulfate solution in distilled water at 35-60°C with continuous stirring for 1.5-4 h followed by addition of coagulation agent, namely alkali or earth alkali metal permanganate to produce coagulation agent concentration in solution of 0.0005-0.03 M. Obtained solution is stirred at 35-60°C for 25-90 min, than ionic force is increased up to 1-3 M, solution is heated up to 60-62°C and stirred at abovementioned temperature for 1-3 h. Further contaminant precipitate obtained in coagulation process is separated by filtration thought filter having pore size from 1 to 25 mum. Filtered solution of non-fragmented (high molecular) DNA is cooled to 0-20°C, alcohol is added to obtain finished concentration of 27043.5 vol. %, Then obtained solution is agitated and deposited with alcohol preparation is filtered and separated, washed with 96 % ethanol and stored under ethanol. Obtained DNA preparation is dissolved in 0.01-4.5 M NaCl aqueous solution at 50°C or less; obtained solution is passed through high pressure homogenizer under pressure up to 2000 kg/cm2, obtained fragmented DNA is treated with alcohol wherein deposited with alcohol fermented sodium DNA is centrifuged and separated. Separated precipitate is rewashed with alcohol and dried in desiccator at 50°C or less to produce powder.

EFFECT: simplified technology for DNA sodium salt production with increased yield without losses of quality.

1 ex, 3 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: raw soft roe should be reduced, treated at certain temperature with 0.2%-acetic acid solution, dehydrated with alcohol, dried to obtain granules, granules should be extracted with sulfuric acid solution at three stages, proteins should be precipitated out of extract by adding triple volume of ethanol, residue should be dissolved, solution should be treated with barium hydroxide up to pH being 7.0-7.5 followed by addition of ammonia up to pH being 10.5-11.5 to separate the residue due to decanting and centrifuging. Solution obtained after decanting and centrifugate should be treated with kieselguhr at heating up to 80 C and filtered upon a Nutch filter, one should apply filtrate through cationite in "H+"-form, eluate should be concentrated due to vacuum evaporation or by applying baromembranous technique, then one should precipitate the product out of eluate with triple volume of alcohol due to a 5-fold reprecipitation along with centrifuging and drying the residue to remove residual moisture and dry ready-to-use product at 55-65 C for 24 h. The present innovation enables to increase the degree of purification of protamine sulfate due to purifying against accompanying foreign proteins.

EFFECT: increased anti-heparin activity.

The invention relates to veterinary medicine, namely to veterinary gynecology

The invention relates to new high-performance technologies to get immunotropic sterile high quality safe drugs on the basis of sodium deoxyribonuclease, obtained from low-fat milk sturgeon, salmon, calf thymus, blood chickens

The invention relates to food industry, namely, oil industry
The invention relates to the fishing industry, in particular to a method for producing a medicinal product from fish liver

FIELD: pharmaceutical technology, pharmacy.

SUBSTANCE: method involves addition sugar-alcohol and/or saccharide showing melting point by 5°C lower or above as compared with the first mentioned sugar-alcohol and/or saccharide to sugar-alcohol and/or saccharide followed by combined treatment of prepared powder by pressing and heating. Invention allows preparing medicinal compositions decomposing in mouth cavity rapidly being without water and showing light using owing to the presence of sufficient strength in preparing, transport in usual using. Method involves mixing, pressing and heating components that represent two or more sugar-alcohol and/or saccharide and active component wherein difference between melting points of one among two or more indicated sugar-alcohol and/or saccharide that shows the higher content and any remaining indicated two or more sugar-alcohol and/or saccharide is 5°C or above. Invention provides preparing strength rapidly soluble tablets.

EFFECT: improved preparing method, improved pharmaceutical properties of composition.

30 cl, 12 tbl, 28 ex

Up!